Yawning behavior for preclinical drug evaluation.
Furukawa
T
T
Department of Pharmacology, School of Medicine, Fukuoka University, Japan.
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000494:pharmacology; D018678:Cholinergic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D015259:Dopamine Agents / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism; D011388:Prolactin / Q000378:metabolism; D011619:Psychotropic Drugs / Q000009:adverse effects* / Q000494:pharmacology; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000378:metabolism; D015000:Yawning / Q000187:drug effects*
D000978:Antiparkinson Agents; D018678:Cholinergic Agents; D015259:Dopamine Agents; D011619:Psychotropic Drugs; D017448:Receptors, Dopamine D2; D011388:Prolactin